{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:11:21Z","timestamp":1792440681175,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40264-024-01471-z","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:17:22Z","timestamp":1723738642000},"page":"1275-1292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-2212","authenticated-orcid":false,"given":"Michele","family":"Fusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Menestrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Recanatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gastone","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"1471_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1126\/science.847460","volume":"196","author":"GL Engel","year":"1977","unstructured":"Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129\u201336.","journal-title":"Science"},{"key":"1471_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.an.11.100182.001353","volume":"11","author":"A Young","year":"1982","unstructured":"Young A. The anthropologies of illness and sickness. Annu Rev Anthropol. 1982;11:257\u201385.","journal-title":"Annu Rev Anthropol"},{"key":"1471_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7326\/0003-4819-88-2-251","volume":"88","author":"A Kleinman","year":"1978","unstructured":"Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978;88:251\u20138.","journal-title":"Ann Intern Med"},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2710.2011.01258.x","volume":"37","author":"S Lorimer","year":"2012","unstructured":"Lorimer S, Cox A, Langford NJ. A patient\u2019s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148\u201352.","journal-title":"J Clin Pharm Ther"},{"key":"1471_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1345\/aph.10094","volume":"34","author":"D-C Suh","year":"2000","unstructured":"Suh D-C, Woodall BS, Shin S-K, Santis ERH-D. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34:1373\u20139.","journal-title":"Ann Pharmacother"},{"key":"1471_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes L, van Hunsel F, Taxis K, van Puijenbroek E. The impact of experiencing adverse drug reactions on the patient\u2019s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39:769\u201376.","journal-title":"Drug Saf"},{"key":"1471_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension. JAMA. 2018;319:483\u201394.","journal-title":"JAMA"},{"key":"1471_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s41687-021-00402-1","volume":"5","author":"S Haag","year":"2021","unstructured":"Haag S, Junge L, Lotz F, McGauran N, Paulides M, Potthast R, et al. Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs. J Patient Rep Outcomes. 2021;5:127.","journal-title":"J Patient Rep Outcomes"},{"key":"1471_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/mds.27668","volume":"34","author":"D Weintraub","year":"2019","unstructured":"Weintraub D. Impulse control disorders in Parkinson\u2019s disease: a 20-year odyssey. Mov Disord Off J Mov Disord Soc. 2019;34:447\u201352.","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"1471_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2021.08.006","volume":"90","author":"M Fusaroli","year":"2021","unstructured":"Fusaroli M, Raschi E, Contin M, Sambati L, Menchetti M, Fioritti A, et al. Impulsive conditions in Parkinson\u2019s disease: a pharmacosurveillance-supported list. Parkinsonism Relat Disord. 2021;90:79\u201383.","journal-title":"Parkinsonism Relat Disord"},{"key":"1471_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/add.16086","volume":"118","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Pellegrini L, Fusaroli R, Raschi E, Menchetti M, Poluzzi E. Behavioral excess and disruptive conduct: a historical and taxonomic approach to the origin of the \u2018impulse control disorders\u2019 diagnostic construct. Addiction. 2023;118:763\u201370.","journal-title":"Addiction"},{"key":"1471_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41:19\u201375.","journal-title":"Drug Saf"},{"key":"1471_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1212\/01.wnl.0000252368.25106.b6","volume":"68","author":"M Tippmann-Peikert","year":"2007","unstructured":"Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68:301\u20133.","journal-title":"Neurology"},{"key":"1471_CR14","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case\u2013control study. Sleep. 2010;33:81\u20137.","journal-title":"Sleep"},{"key":"1471_CR15","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"J-C Corvol","year":"2018","unstructured":"Corvol J-C, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91:e189-201.","journal-title":"Neurology"},{"key":"1471_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ijnp\/pyac031","volume":"25","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, et al. Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol. 2022;25:727\u201336.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1471_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/JCP.0000000000001896","volume":"44","author":"BD Williams","year":"2024","unstructured":"Williams BD, Lee K, Ewah SO, Neelam K. Aripiprazole and other third-generation antipsychotics as a risk factor for impulse control disorders: a systematic review and meta-analysis. J Clin Psychopharmacol. 2024;44:39\u201348.","journal-title":"J Clin Psychopharmacol"},{"key":"1471_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.neurol.2018.07.005","volume":"174","author":"M B\u00e9reau","year":"2018","unstructured":"B\u00e9reau M, Fleury V, Bouthour W, Castrioto A, Lhomm\u00e9e E, Krack P. Hyperdopaminergic behavioral spectrum in Parkinson\u2019s disease: a review. Rev Neurol (Paris). 2018;174:653\u201363.","journal-title":"Rev Neurol (Paris)."},{"key":"1471_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s11136-022-03321-w","volume":"32","author":"A Jeyadevan","year":"2023","unstructured":"Jeyadevan A, Bakeberg M, Byrnes M, Kenna J, McGregor S, Ghosh S, et al. Quality of life implications for elevated trait impulsivity in people with Parkinson\u2019s disease. Qual Life Res. 2023;32:1143\u201350.","journal-title":"Qual Life Res"},{"key":"1471_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00702-023-02588-8","volume":"130","author":"B Leplow","year":"2023","unstructured":"Leplow B, Renftle D, Thomas M, Michaelis K, Solbrig S, Maetzler W, et al. Characteristics of behavioural addiction in Parkinson\u2019s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case\u2013control study. J Neural Transm. 2023;130:125\u201333.","journal-title":"J Neural Transm"},{"key":"1471_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","volume":"21","author":"AL Phu","year":"2014","unstructured":"Phu AL, Xu Z, Brakoulias V, Mahant N, Fung VSC, Moore GD, et al. Effect of impulse control disorders on disability and quality of life in Parkinson\u2019s disease patients. J Clin Neurosci. 2014;21:63\u20136.","journal-title":"J Clin Neurosci"},{"key":"1471_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2015.04.013","volume":"353","author":"M Skorvanek","year":"2015","unstructured":"Skorvanek M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, et al. Relationship between the non-motor items of the MDS\u2013UPDRS and quality of Life in patients with Parkinson\u2019s disease. J Neurol Sci. 2015;353:87\u201391.","journal-title":"J Neurol Sci"},{"key":"1471_CR23","doi-asserted-by":"publisher","first-page":"16893","DOI":"10.1038\/s41598-020-73756-z","volume":"10","author":"S Jes\u00fas","year":"2020","unstructured":"Jes\u00fas S, Labrador-Espinosa MA, Adarmes AD, M\u00e9ndel-Del Barrio C, Mart\u00ednez-Castrillo JC, Alonso-C\u00e1novas A, et al. Non-motor symptom burden in patients with Parkinson\u2019s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. Sci Rep. 2020;10:16893.","journal-title":"Sci Rep"},{"key":"1471_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","volume":"12","author":"A Schrag","year":"2006","unstructured":"Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12:35\u201341.","journal-title":"Parkinsonism Relat Disord"},{"key":"1471_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","volume":"88","author":"A Antonini","year":"2017","unstructured":"Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2017;88:317\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1471_CR26","unstructured":"Fusaroli M. Updating our approach to study adverse reactions. Upps Rep [Internet]. 2024. https:\/\/uppsalareports.org\/articles\/updating-our-approach-to-study-adverse-reactions\/. Accessed 11 Jun 2024."},{"key":"1471_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40264-018-0713-8","volume":"42","author":"G Castillon","year":"2019","unstructured":"Castillon G, Salvo F, Moride Y. The social impact of suspected adverse drug reactions: an analysis of the Canada vigilance spontaneous reporting database. Drug Saf. 2019;42:27\u201334.","journal-title":"Drug Saf"},{"key":"1471_CR28","unstructured":"FAERS Quarterly Data Extract Files [Internet]. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 24 Dec 2022."},{"key":"1471_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40264-015-0264-1","volume":"38","author":"L H\u00e4rmark","year":"2015","unstructured":"H\u00e4rmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38:337\u201347.","journal-title":"Drug Saf"},{"key":"1471_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","volume":"39","author":"L H\u00e4rmark","year":"2016","unstructured":"H\u00e4rmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39:883\u201390.","journal-title":"Drug Saf"},{"key":"1471_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13098","volume":"83","author":"P In\u00e1cio","year":"2017","unstructured":"In\u00e1cio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227\u201346.","journal-title":"Br J Clin Pharmacol"},{"key":"1471_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/pds.3687","volume":"24","author":"L Rolfes","year":"2015","unstructured":"Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24:152\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1471_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","volume":"41","author":"S Watson","year":"2018","unstructured":"Watson S, Chandler RE, Taavola H, H\u00e4rmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using vigibase: results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018;41:203\u201312.","journal-title":"Drug Saf"},{"key":"1471_CR34","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3389\/fphar.2021.740707","volume":"12","author":"M Fusaroli","year":"2021","unstructured":"Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a network-based signal detection tool: the COVID-19 adversome in the FDA adverse event reporting system. Front Pharmacol. 2021;12:3542.","journal-title":"Front Pharmacol"},{"key":"1471_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3758\/s13428-017-0862-1","volume":"50","author":"S Epskamp","year":"2018","unstructured":"Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: a tutorial paper. Behav Res Methods. 2018;50:195\u2013212.","journal-title":"Behav Res Methods"},{"key":"1471_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2307\/2340126","volume":"75","author":"GU Yule","year":"1912","unstructured":"Yule GU. On the methods of measuring association between two attributes. J R Stat Soc. 1912;75:579\u2013652.","journal-title":"J R Stat Soc"},{"key":"1471_CR37","doi-asserted-by":"publisher","unstructured":"Chen SF, Goodman J. An empirical study of smoothing techniques for language modeling. Proceedings of 34th Annual Meet Assoc Comput Linguist [Internet]. USA: Association for Computational Linguistics; 1996. p. 310\u20138. https:\/\/doi.org\/10.3115\/981863.981904. Accessed 17 Mar 2023.","DOI":"10.3115\/981863.981904"},{"key":"1471_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v035.i03","volume":"35","author":"M Scutari","year":"2010","unstructured":"Scutari M. Learning Bayesian networks with the bnlearn R package. J Stat Softw. 2010;35:1\u201322.","journal-title":"J Stat Softw"},{"key":"1471_CR39","doi-asserted-by":"crossref","unstructured":"Briganti G, Scutari M, McNally RJ. A tutorial on Bayesian Networks for psychopathology researchers [Internet]. OSF; 2021. https:\/\/osf.io\/h4vxa. Accessed 31 Mar 2024.","DOI":"10.31234\/osf.io\/h4vxa"},{"key":"1471_CR40","unstructured":"Fusaroli M, Giunchi V. DiAna. An open access toolkit for DIsproportionality ANAlysis and other pharmacovigilance investigations in the FAERS. [Internet]. 2024. https:\/\/github.com\/fusarolimichele\/DiAna_package."},{"key":"1471_CR41","unstructured":"MedDRA [Internet]. https:\/\/www.meddra.org\/. Accessed 4 Feb 2023."},{"key":"1471_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.07.23291076v1","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Giunchi V, Battini V, Puligheddu S, Khouri C, Carnovale C, et al. Standardization of drug names in the FDA adverse event reporting system: the DiAna dictionary [Internet]. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.06.07.23291076v1.","journal-title":"medRxiv"},{"key":"1471_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39:469\u201390.","journal-title":"Drug Saf"},{"key":"1471_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"1471_CR45","first-page":"22","volume":"16","author":"KW Church","year":"1990","unstructured":"Church KW, Hanks P. Word association norms, mutual information, and lexicography. Comput Linguist. 1990;16:22\u20139.","journal-title":"Comput Linguist"},{"key":"1471_CR46","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3758\/BRM.41.3.647","volume":"41","author":"G Recchia","year":"2009","unstructured":"Recchia G, Jones MN. More data trumps smarter algorithms: comparing pointwise mutual information with latent semantic analysis. Behav Res Methods. 2009;41:647\u201356.","journal-title":"Behav Res Methods"},{"key":"1471_CR47","unstructured":"Role F, Nadif M. Handling the impact of low frequency events on co-occurrence based measures of word similarity\u2014a case study of pointwise mutual information. 2011."},{"key":"1471_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-022-01269-x","volume":"46","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Pelletti G, Giunchi V, Pugliese C, Bartolucci M, Necibi EN, et al. Deliberate self-poisoning: real-time characterization of suicidal habits and toxidromes in the food and drug administration adverse event reporting system. Drug Saf. 2023;46:283\u201395.","journal-title":"Drug Saf"},{"key":"1471_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00603-8","author":"O Pauline","year":"2023","unstructured":"Pauline O, Robert M, Bernardeau C, Hlavaty A, Fusaroli M, Roustit M, et al. Assessment of reported adverse events after interchanging between TNF-\u03b1 inhibitor biosimilars in the WHO pharmacovigilance database. BioDrugs [Internet]. 2023. https:\/\/doi.org\/10.1007\/s40259-023-00603-8.","journal-title":"BioDrugs [Internet]"},{"key":"1471_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1142\/S0129065705000219","volume":"15","author":"R Orre","year":"2005","unstructured":"Orre R, Bate A, Nor\u00e9n GN, Swahn E, Arnborg S, Edwards IR. A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst. 2005;15:207\u201322.","journal-title":"Int J Neural Syst"},{"key":"1471_CR51","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1038\/srep05918","volume":"4","author":"CD van Borkulo","year":"2014","unstructured":"van Borkulo CD, Borsboom D, Epskamp S, Blanken TF, Boschloo L, Schoevers RA, et al. A new method for constructing networks from binary data. Sci Rep. 2014;4:5918.","journal-title":"Sci Rep"},{"key":"1471_CR52","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevE.69.026113","volume":"69","author":"MEJ Newman","year":"2004","unstructured":"Newman MEJ, Girvan M. Finding and evaluating community structure in networks. Phys Rev E. 2004;69: 026113.","journal-title":"Phys Rev E"},{"key":"1471_CR53","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevE.69.066133","volume":"69","author":"MEJ Newman","year":"2004","unstructured":"Newman MEJ. Fast algorithm for detecting community structure in networks. Phys Rev E. 2004;69: 066133.","journal-title":"Phys Rev E"},{"key":"1471_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1469-8137.1912.tb05611.x","volume":"11","author":"P Jaccard","year":"1912","unstructured":"Jaccard P. The distribution of the flora in the alpine zone. 1. New Phytol. 1912;11:37\u201350.","journal-title":"New Phytol"},{"key":"1471_CR55","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1109\/TKDE.2016.2551240","volume":"28","author":"M Rezaei","year":"2016","unstructured":"Rezaei M, Fr\u00e4nti P. Set matching measures for external cluster validity. IEEE Trans Knowl Data Eng. 2016;28:2173\u201386.","journal-title":"IEEE Trans Knowl Data Eng"},{"key":"1471_CR56","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.1038\/s41598-019-44892-y","volume":"9","author":"AJ Gates","year":"2019","unstructured":"Gates AJ, Wood IB, Hetrick WP, Ahn Y-Y. Element-centric clustering comparison unifies overlaps and hierarchy. Sci Rep. 2019;9:8574.","journal-title":"Sci Rep"},{"key":"1471_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-3-540-45167-9_14","volume-title":"Learn Theory Kernel Mach","author":"M Meil\u0103","year":"2003","unstructured":"Meil\u0103 M. Comparing clusterings by the variation of information. In: Sch\u00f6lkopf B, Warmuth MK, editors. Learn Theory Kernel Mach. Berlin: Springer; 2003. p. 173\u201387."},{"key":"1471_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/brain.2011.0038","volume":"1","author":"QK Telesford","year":"2011","unstructured":"Telesford QK, Joyce KE, Hayasaka S, Burdette JH, Laurienti PJ. The ubiquity of small-world networks. Brain Connect. 2011;1:367\u201375.","journal-title":"Brain Connect"},{"key":"1471_CR59","unstructured":"Fusaroli M, Polizzi S, Menestrina L, Giunchi V. Unveiling the hidden toll of drug-induced impulse control disorders. 2023. https:\/\/osf.io\/k9v6s\/. Accessed 20 Aug 2023."},{"key":"1471_CR60","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.neurol.2020.08.006","volume":"177","author":"H El Otmani","year":"2021","unstructured":"El Otmani H, Sabiry S, Bellakhdar S, El Moutawakil B, Abdoh RM. Othello syndrome in Parkinson\u2019s disease: a diagnostic emergency of an underestimated condition. Rev Neurol (Paris). 2021;177:690\u20133.","journal-title":"Rev Neurol (Paris)."},{"key":"1471_CR61","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589\u201395.","journal-title":"Arch Neurol"},{"key":"1471_CR62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.parkreldis.2013.02.007","volume":"19","author":"G Santangelo","year":"2013","unstructured":"Santangelo G, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson\u2019s disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19:645\u201353.","journal-title":"Parkinsonism Relat Disord"},{"key":"1471_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neurobiolaging.2018.11.021","volume":"75","author":"H Jim\u00e9nez-Urbieta","year":"2019","unstructured":"Jim\u00e9nez-Urbieta H, Gago B, Quiroga-Varela A, Rodr\u00edguez-Chinchilla T, Merino-Gal\u00e1n L, Oregi A, et al. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson\u2019s disease. Neurobiol Aging. 2019;75:126\u201335.","journal-title":"Neurobiol Aging"},{"key":"1471_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbr.2012.04.027","volume":"233","author":"JL Riddle","year":"2012","unstructured":"Riddle JL, Rokosik SL, Napier TC. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson\u2019s disease and controls. Behav Brain Res. 2012;233:15\u201323.","journal-title":"Behav Brain Res"},{"key":"1471_CR65","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ana.25581","volume":"86","author":"J Mar\u00edn-Lahoz","year":"2019","unstructured":"Mar\u00edn-Lahoz J, Sampedro F, Martinez-Horta S, Pagonabarraga J, Kulisevsky J. Depression as a risk factor for impulse control disorders in Parkinson disease. Ann Neurol. 2019;86:762\u20139.","journal-title":"Ann Neurol"},{"key":"1471_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114411","volume":"309","author":"AW Blum","year":"2022","unstructured":"Blum AW, Jacobson K, Grant JE. Legal settlements and the reporting of adverse drug events: insights from the aripiprazole products liability litigation. Psychiatry Res. 2022;309: 114411.","journal-title":"Psychiatry Res"},{"key":"1471_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2021.102199","volume":"122","author":"GN Nor\u00e9n","year":"2021","unstructured":"Nor\u00e9n GN, Meldau E-L, Chandler RE. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance. Artif Intell Med. 2021;122: 102199.","journal-title":"Artif Intell Med"},{"key":"1471_CR68","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69:986\u201396.","journal-title":"Ann Neurol"},{"key":"1471_CR69","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0097-2018","volume":"28","author":"JF Masa","year":"2019","unstructured":"Masa JF, P\u00e9pin J-L, Borel J-C, Mokhlesi B, Murphy PB, S\u00e1nchez-Quiroga M\u00c1. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28: 180097.","journal-title":"Eur Respir Rev"},{"key":"1471_CR70","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00125-013-3157-9","volume":"57","author":"P de Jonge","year":"2014","unstructured":"de Jonge P, Alonso J, Stein DJ, Kiejna A, Aguilar-Gaxiola S, Viana MC, et al. Associations between DSM-IV mental disorders and diabetes mellitus: a role for impulse control disorders and depression. Diabetologia. 2014;57:699\u2013709.","journal-title":"Diabetologia"},{"key":"1471_CR71","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2009;24:1561\u201370.","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"1471_CR72","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1468-1331.2011.03432.x","volume":"18","author":"D Okai","year":"2011","unstructured":"Okai D, Samuel M, Askey-Jones S, David AS, Brown RG. Impulse control disorders and dopamine dysregulation in Parkinson\u2019s disease: a broader conceptual framework. Eur J Neurol. 2011;18:1379\u201383.","journal-title":"Eur J Neurol"},{"key":"1471_CR73","doi-asserted-by":"crossref","unstructured":"De la Casa-Fages B, Grandas F. Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson\u2019s disease. Neurol Res Int [Internet]. 2011. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3216377\/. Accessed 16 June 2021.","DOI":"10.1155\/2011\/759895"},{"key":"1471_CR74","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2015;30:121\u20137.","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"1471_CR75","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2016.12.070","volume":"374","author":"XX Yu","year":"2017","unstructured":"Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: a comprehensive review. J Neurol Sci. 2017;374:53\u20135.","journal-title":"J Neurol Sci"},{"key":"1471_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00129","author":"H Kataoka","year":"2018","unstructured":"Kataoka H, Sugie K. Delusional jealousy (Othello syndrome) in 67 patients with Parkinson\u2019s disease. Front Neurol. 2018. https:\/\/doi.org\/10.3389\/fneur.2018.00129.","journal-title":"Front Neurol"},{"key":"1471_CR77","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0037-1601887","volume":"37","author":"AM Lopez","year":"2017","unstructured":"Lopez AM, Weintraub D, Claassen DO. Impulse control disorders and related complications of Parkinson\u2019s disease therapy. Semin Neurol. 2017;37:186\u201392.","journal-title":"Semin Neurol"},{"key":"1471_CR78","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/mds.25679","volume":"29","author":"KS Goerlich-Dobre","year":"2014","unstructured":"Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, M\u00f6ller B, et al. Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2014;29:214\u201320.","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"1471_CR79","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neubiorev.2013.11.001","volume":"38","author":"C Vriend","year":"2014","unstructured":"Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S, et al. Depression and impulse control disorders in Parkinson\u2019s disease: two sides of the same coin? Neurosci Biobehav Rev. 2014;38:60\u201371.","journal-title":"Neurosci Biobehav Rev"},{"key":"1471_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013062\/full","author":"NR Plummer","year":"2018","unstructured":"Plummer NR, Tam AW, Mulvaney CA, Preston NJ, Laha SK. Dopamine agonists for traumatic brain injury. Cochrane Database Syst Rev [Internet]. 2018. https:\/\/doi.org\/10.1002\/14651858.CD013062\/full.","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"1471_CR81","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00213-009-1671-8","volume":"207","author":"MW Feltenstein","year":"2009","unstructured":"Feltenstein MW, Do PH, See RE. Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse. Psychopharmacology. 2009;207:401\u201311.","journal-title":"Psychopharmacology"},{"key":"1471_CR82","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.biopsych.2006.04.010","volume":"61","author":"MW Feltenstein","year":"2007","unstructured":"Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry. 2007;61:582\u201390.","journal-title":"Biol Psychiatry"},{"key":"1471_CR83","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/109786","volume":"2014","author":"M Pettorruso","year":"2014","unstructured":"Pettorruso M, De Risio L, Martinotti G, Di Nicola M, Ruggeri F, Conte G, et al. Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives. BioMed Res Int. 2014;2014: 109786.","journal-title":"BioMed Res Int"},{"key":"1471_CR84","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/13543784.2016.1175431","volume":"25","author":"G Martinotti","year":"2016","unstructured":"Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, et al. Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs. 2016;25:719\u201328.","journal-title":"Expert Opin Investig Drugs"},{"key":"1471_CR85","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/ph17040535","volume":"17","author":"S Chiappini","year":"2024","unstructured":"Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G, et al. Investigating the effectiveness of brexpiprazole in subjects with schizophrenia spectrum illness and co-occurring substance use disorder: a prospective, multicentric, real-world study. Pharmaceuticals. 2024;17:535.","journal-title":"Pharmaceuticals"},{"key":"1471_CR86","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.29700","volume":"39","author":"I Debove","year":"2024","unstructured":"Debove I, Paschen S, Amstutz D, Cardoso F, Corvol J-C, Fung VSC, et al. Management of impulse control and related disorders in Parkinson\u2019s disease: an expert consensus. Mov Disord. 2024;39:235\u201348.","journal-title":"Mov Disord"},{"key":"1471_CR87","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","volume":"48","author":"D Aarsland","year":"2000","unstructured":"Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938\u201342.","journal-title":"J Am Geriatr Soc"},{"key":"1471_CR88","doi-asserted-by":"crossref","unstructured":"Fusaroli M, Mitchell J, Rudolph A, Rocca E, Fusaroli R. Causal inference tools for pharmacovigilance: using causal graphs to systematize biases, plan disproportionality analyses, and reduce the risk of spin. [Internet]. OSF Preprints; 2024. osf.io\/h5w9u.","DOI":"10.31219\/osf.io\/h5w9u"},{"key":"1471_CR89","unstructured":"Fusaroli M, Giunchi V. DiAna: Repository for FAERS cleaning and analysis. 2023. https:\/\/osf.io\/zqu89\/. Accessed 20 Aug 2023."},{"key":"1471_CR90","unstructured":"R: The R Project for Statistical Computing [Internet]. https:\/\/www.r-project.org\/. Accessed 4 Feb 2023."},{"key":"1471_CR91","unstructured":"Welcome to Python.org [Internet]. Python.org. 2023. https:\/\/www.python.org\/. Accessed 4 Feb 2023."},{"key":"1471_CR92","unstructured":"Csardi G, Nepusz T. The igraph software package for complex network research."},{"key":"1471_CR93","unstructured":"Revelle W. Procedures for psychological, psychometric, and personality research [Internet]. R package version 2.2.9. Northwestern University, Evanston, Illinois. 2022. https:\/\/CRAN.R-project.org\/package=psych."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01471-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:07:26Z","timestamp":1731924446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01471-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01471-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.17.23298635","asserted-by":"object"}]},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Alma Mater Studiorum - Universit\u00e0 di Bologna within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest specific for this research. Fabrizio De Ponti is an Editorial Board member of Drug Safety. Fabrizio De Ponti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable because spontaneous reports of the FAERS are anonymous and publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because spontaneous reports of the FAERS are anonymous and publicly available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable because spontaneous reports of the FAERS are anonymous and publicly available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data we used come from the FDA Adverse Event Reporting System (FAERS) and is made publicly available by the FDA as quarterly data downloadable at\n                      \n                      . The algorithm for cleaning FAERS data is open-source at\n                      \n                      , and the cleaned database is available on an OSF repository [\n                      \n                      ] and through the R package DiAna [\n                      \n                      ].","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code for the project is available on an OSF repository [\n                      \n                      ], the function for the Ising network is also available in the DiAna package (cfr. \u201cnetwork_analysis()\u201d) [\n                      \n                      ]. Analyses were performed using R (version 4.2.1) [\n                      \n                      ] and Python (version 3.8.16) [\n                      \n                      ]. We relied on several essential packages for network analysis: <i>IsingFit<\/i> [\n                      \n                      ], <i>igraph<\/i> [\n                      \n                      ], <i>psych<\/i> [\n                      \n                      ], and <i>bnlearn<\/i> [\n                      \n                      ].","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MF, SP, LM, conceptualized and designed the study. MF, SP, LM developed the methodology. The formal analysis was performed by MF, SP, LM, VG. MF, SP, VG performed the visualization. MF, SP, LM, VG wrote the original draft. All the authors strongly contributed to the interpretation of results, and to the review and editing of the draft. All the authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}